Showing 591-600 of 1066 results for "".
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31118/Recent advancements in neurology highlight significant progress and emerging insights into Alzheimer’s disease (AD) and related neurological conditions. A pivotal study published in the FASEB Journal reveals that amyloid β-derived diffusible ligand (ADDL) in AD patients disrupts insulin signaling by
- What Should We Do About Asymptomatic AVMs?https://practicalneurology.com/columns/practice-management/what-should-we-do-about-asymptomatic-avms/31127/Clinical Decision-Making in the Management of Asymptomatic Cerebral Arteriovenous MalformationsCerebral arteriovenous malformations (AVMs) present a significant clinical challenge, especially when asymptomatic. The primary dilemma revolves around balancing the natural hemorrhage risk against the pot
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31133/Optimizing Financial Management in Neurological Practices: A Focus on Income StatementsManaging a busy neurological practice demands not only clinical expertise but also robust financial acumen. In today’s competitive healthcare environment, understanding and utilizing financial statements is crucia
- The Night Shift: Putting Sleep Studies to Work for Youhttps://practicalneurology.com/diseases-diagnoses/sleep/pn0707-sleep-studies-pdf/31153/Enhancing Neurological Diagnoses with Sleep StudiesSleep studies, particularly polysomnography (PSG), are becoming increasingly vital in neurology for accurately diagnosing sleep-related disorders. Despite patients’ reluctance to undergo overnight testing, the objective data obtained from PSGs provi
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31144/Participating in clinical trials presents a valuable opportunity for neurology practices to expand services and enhance revenue streams. Clinical trials are integral to the drug development process, enabling the pharmaceutical industry to assess the safety and efficacy of new neurological treatments
- Movement Disorders Focushttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0607-movementdisorder-pdf/31164/Sydenham’s Chorea in Adolescents: Clinical Presentation and ManagementSydenham’s chorea is a critical movement disorder in adolescents, often emerging as a delayed neurological complication of acute rheumatic fever (ARF) following a Group A streptococcal infection. While clinicians might first consi
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0407-painmngmt-pdf/31193/Chronic Pain Management: Addressing Potential Bias in Clinical AssessmentsChronic pain remains a significant challenge in neurology, often complicated by the subjective nature of pain assessment. In the article "Are You Guilty of Bias When Encountering Unexplained Pain?" by Charles Argoff, MD, publi
- Seizures, AEDs and Pregnancy: A Dangerous Combinationhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0407-epilepsy-pdf/31188/Managing epilepsy in women who are pregnant or planning pregnancy presents significant challenges for neurologists. Seizures during pregnancy pose risks to both the mother and the unborn child, while the use of anti-epileptic drugs (AEDs) can lead to congenital malformations and potential cognitive
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31191/Advancements in Neurology: Key Developments in Epilepsy Management and BeyondRecent breakthroughs in epilepsy care are equipping neurologists with enhanced therapeutic options and optimizing existing treatments. A pivotal study published in the April 10th issue of *Neurology* highlights the efficacy
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/PN1206Epilepsy-pdf/31237/The Role of Generic Antiepileptic Drugs in Epilepsy ManagementEffective epilepsy treatment aims to achieve seizure freedom without adverse side effects. According to Kwan and Brodie, approximately 64% of patients reach this goal using either monotherapy or a combination of two antiseizure medication